{"name":"Jeffrey S Heier","slug":"jeffrey-s-heier","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1JNmR6eHc2NjFMTDNac3A3SFh6bmdwcWJ5RGNSQ0pOZl9OT29qTDZ5YnVONWhPTThVRFB1aWJ1MWdBYUUteHU4MUNTVkJQZ2hPcmgyME1yeXUwelJJWVotS1IxUURPNjl1aURZRmlsd1YtNENpenVLNTQ2bw?oc=5","date":"2026-03-24","type":"trial","source":"Healio","summary":"Addressing the Persistent Burden of Wet AMD with Innovative Trial Design - Healio","headline":"Addressing the Persistent Burden of Wet AMD with Innovative Trial Design","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVjlPa2dQZFJKMktCMFZULXZBYTlJSzdfSW5weHVYQUFjMnh6Vi11akN0Z3A0YWxldk8tUE9xVFlFdElKRDVCYlhMOWNsT2ZBNzdlenlYd2trbFdEQm12emV3SEFuS2VGVVZGeW12Ykc3NDZlelBwdzlxMUlkRnIwMFA3eEsxdHRCQ2N0bWM2dWFCMDRwWDZPb2RMZ1pqUXlERlZVb2V6TXZmeW9xRGxDaGZZUFBza3hSek9teXdUb3Y?oc=5","date":"2025-07-28","type":"pipeline","source":"PharmTech.com","summary":"Boehringer Ingelheim, Re-Vana Therapeutics to Collaborate on Long-Acting Ophthalmic Therapies - PharmTech.com","headline":"Boehringer Ingelheim, Re-Vana Therapeutics to Collaborate on Long-Acting Ophthalmic Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPZlNTTUZ0c29NWFloOUVxV2U2ZldqdVVBTVBnUmFMM2NJaXlSOXpXZzdEWUNaV29JbFJLdm9WVHhaazBqQVlxdjVGSXdJaTQtOHFXa3NJai1JNzlTYXE5Z3NEYXdyaXBfV1o1dWtfNG1FMXI5VTlMVTE5Zzk2ellkMmhBTEtMNW5rWWJiOFluT3ZEQVNnM1Yw?oc=5","date":"2025-07-04","type":"pipeline","source":"PharmTech.com","summary":"Advanced Solutions for Sustained Delivery of Ocular Therapies - PharmTech.com","headline":"Advanced Solutions for Sustained Delivery of Ocular Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1vQUExMERQMElsRkhiNTVxSE1yWDc0aWFmM0tKQ0Z3eEVEVEJNUnhjdEdDNk9rUjJhSkxUMnFGUlFaM0d6ZUdubERxWkFYLUZjWm9VaWtvR1NMVHctR0NZ?oc=5","date":"2025-01-13","type":"trial","source":"nature.com","summary":"Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial | Eye - nature.","headline":"Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related mac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOLU1wMXJfNGpZYnZNaUFKaDYwRFlfVHZJNDExMWFzSWFvaTB3WHVvN2tnSFA1VUFIcXJoM2YzN2o4QUlmNDhONVl5c2JMeGh3RFUyRFJiWHdhYWswbG85SXBVUFAxTFloTnVTdThrUklZblZ4LUx0M0hwUnNwZ1hFcGcxbUFuWm14M3F0amdzRG5YckJHXzFlRDVWbTkyTnlNYWRUcTBWbjM2VjlXbW5PazRwNl82WE1YNzZ5T3pnMA?oc=5","date":"2024-09-19","type":"trial","source":"Modern Retina","summary":"Alkeus Pharmaceuticals shares results of SAGA study of oral gildeuretinol acetate for GA - Modern Retina","headline":"Alkeus Pharmaceuticals shares results of SAGA study of oral gildeuretinol acetate for GA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQX1NRMGNtU3dTOW5URDVzVE1KdDVMOWc5T3N5UWxBd3d6SWZRRkU3QzY4aWw3ZnFGVl9KWWZ5bHpVaHphSUQxQkxYcmlUZlNqZUc3QmlPc0JYUlg1T1RDdmNQZWpmcG5XLU1UakdnbDBiNXFNMUhTdjFoVlVVZlY5Y21zd21JeTJnUVE3cW5nTjZvMTF6cU85RGgtQU5QWHVfOGNyTTY0X01McndRVXc?oc=5","date":"2024-02-22","type":"pipeline","source":"Ophthalmology Times","summary":"Ocular Therapeutix announces updates to leadership, Board of Directors - Ophthalmology Times","headline":"Ocular Therapeutix announces updates to leadership, Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNOUZDRlRYSWJSVmZTbXRIWmd2WFlVMldnWm41RW8yNUkxdklWWHVIeXFNV29BRkdZUmRTU0l4MjlIQjhUYml6bjZqRGhzR0JOVlBNdGdlZ2d1Q2NXbjZUMzFzaEFtX1Z6dWx2V3pIMHlMYU5uOThOWmVpazhGeEZEZ2UxTkF0anZJUllpYXFMdXVYZU1PSW1mOEZZNFRFcXJlMGpNNUhUTHNKSlFJTnYzODBWRkFnUHFYd1hz?oc=5","date":"2023-03-29","type":"pipeline","source":"The Boston Globe","summary":"Waltham biotech’s vision loss drug helps slow a form of macular degeneration - The Boston Globe","headline":"Waltham biotech’s vision loss drug helps slow a form of macular degeneration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNcjJzY0JrUGFyTlBPSTFfMWc1ZWpLbFJLTlh4UHREdFBjcmI0a1dNQi1uakd5c2tPZzVJN082bmswQ2tjczV4NGdGaXd5dFhNbVhUU1VBSUlEbF9jTUIteE1YSG5qaVZtQkxVdnJVT255cDljUnd1aXR1UXRpczY0Y3RaNzlPN1hLdkNV?oc=5","date":"2022-01-24","type":"trial","source":"The Lancet","summary":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-infer","headline":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular dege","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE44R2NuRTNmajB0SllwaUs5SnlqNFkxTmpfS0xNX2hGLXFOckN2N1ViaWtRUXRlOXI4QkV3UE54VURpbXUzeDJFOU9acnJvRFAzU3cyZ2RNd0VTd2gzUkJB?oc=5","date":"2006-10-05","type":"pipeline","source":"NEJM","summary":"Ranibizumab for Neovascular Age-Related Macular Degeneration - NEJM","headline":"Ranibizumab for Neovascular Age-Related Macular Degeneration","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}